Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4-dihydro-7-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-pyrimido[4,5-d]pyrimidin-2(1H)-one
Purity: ≥98%
Formula Markup: C30H37N7O2
Formula Weight: 527.7
CAS Number: 2172617-15-9
Notes: YKL-06-061 is an inhibitor of salt-inducible kinase 1 (SIK1), SIK2, and SIK3 (IC50s = 6.56, 1.77, and 20.5 nM, respectively).{66901} It is selective for these SIKs over a panel of 468 additional kinases at 1 µM but does inhibit FRK, CSF1R, p38α, p38β, EphB1, and TNK2 (IC50s = 1.1, 9.66, 10.1, 9.64, 16.4, and 10.5 nM, respectively) and to a lesser extent KIT, Src, BRK, PDGFRβ, and NLK (IC50s = 153, 58.8, 24.1, 103, and 132 nM, respectively). YKL-06-061 (37.5 mM) induces pigmentation in human breast skin explants. In vivo, YKL-06-061 (20 mg/kg) decreases seizure severity in a mouse model of epilepsy induced by pentylenetetrazole (PTZ; Item No. 18682).{66902}
English
Deutsch
